Start Over

Gamma Knife Radiosurgery in Recurrent Glioblastoma.

Authors :: Frischer JM
Marosi C
Woehrer A
Hainfellner JA
Dieckmann KU
Eiter H
Wang WT
Mallouhi A
Ertl A
Knosp E
Filipits M
Kitz K
Gatterbauer B
Source :: Stereotactic and functional neurosurgery [Stereotact Funct Neurosurg] 2016; Vol. 94 (4), pp. 265-272. Date of Electronic Publication: 2016 Oct 08.
Publication Year :: 2016
Abstract: Background: We evaluated Gamma Knife radiosurgery (GKRS) as a treatment option for patients with recurrent glioblastoma.<br />Patients and Methods: 42 patients with histopathologically diagnosed recurrent grade IV tumor were treated with GKRS. All patients had undergone standard multimodal first-line treatment. The average time from diagnosis to GKRS was 17.0 months. The median target volume was 5.1 cm3. The median margin dose was 10 Gy and the median central dose 20 Gy. In a subset of patients, O6-methylguanine methyltransferase (MGMT) promoter methylation analysis by pyrosequencing was performed.<br />Results: Most patients did not develop complications after GKRS. Time to radiological progression after initial GKRS was 4.4 months (95% CI: 3.1-5.7 months). Radiological progression mainly occurred beyond the GKRS-irradiated area. The median survival time after initial GKRS was 9.6 months (95% CI: 7.7-11.5 months). The median overall survival time from diagnosis was 25.6 months (95% CI: 21.8-29.3 months). Patients with MGMT promoter methylation survived significantly longer (33.4 months; 95% CI: 21.2-45.5 months) compared to patients without MGMT promoter methylation (16.0 months; 95% CI: 8.0-23.9 months).<br />Conclusion: GKRS seems to be a relatively safe salvage treatment option for recurrent glioblastoma for highly selected patients but must be seen as part of a multimodal treatment algorithm.<br /> (© 2016 S. Karger AG, Basel.)